

VFC Resolution Update: Pneumococcal Vaccines

**Jeanne M. Santoli (jsantoli@cdc.gov)
Immunization Services Division
National Center for Immunization and
Respiratory Diseases
October 22, 2008**



**DEPARTMENT OF HEALTH AND HUMAN SERVICES
CENTERS FOR DISEASE CONTROL AND PREVENTION**



SAFER · HEALTHIER · PEOPLE

Changes to Current Resolution

- **Polysaccharide vaccine**
 - Eligible Groups
 - Recommended Schedule
- **Pneumococcal vaccine**
 - Recommended Schedule

Polysaccharide Vaccine, Eligible Groups

Eligible Groups Children and adolescents aged 2-18 years who have functional or anatomical asplenia, immunocompromising illness or medications, chronic illness (as specified above), who are American Indian or Alaska Native (**when deemed appropriate by relevant public health authorities based on local circumstances**), or who have received a bone marrow transplant.

Polysaccharide Vaccine, Recommended Schedule

For children who are immunocompromised or who have functional or anatomical asplenia: a single revaccination is recommended **if 5 or more years have elapsed** since the previous dose.

Conjugate Vaccine, Recommended Schedule

American Indian and Alaska Native children, 24-59 months, who have received the pneumococcal conjugate vaccine, may receive a single dose of polysaccharide vaccine after conjugate vaccination **when deemed appropriate by relevant public health authorities based on local circumstances.**

Simplification of the VFC Resolutions

- **Currently VFC resolutions provide information about eligible groups, recommended schedule, dosage intervals, recommended dosage, and contraindications/precautions**
- **Much of this information is detailed in the ACIP recommendations**
- **CDC is working to identify ways to streamline the VFC resolutions, pointing to the ACIP recommendations and avoiding rewriting those recommendations to the extent possible**